Orrick represented Credit Suisse and Jefferies as underwriters for a follow-on public offering of 2,695,313 shares of common stock by Intercept Pharmaceuticals, Inc. (“Intercept”), including shares…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
